MedTrace Logo

Dose Study of ANX1502 in Healthy Volunteers

NCT05521269 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2024-12-27

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ANX1502 (prodrug) and ANX1439 (active drug) in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

ANX1502

ANX1502 is a prodrug of ANX1439.

DRUG

Placebo

Placebo comparator.

Sponsors & Collaborators

  • Annexon, Inc.

    lead INDUSTRY

Principal Investigators

  • Olga Bandman · Annexon, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-27
Primary Completion
2024-11-19
Completion
2024-11-19

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05521269 on ClinicalTrials.gov